UK-based specials manufacturer Quantum Pharmaceutical has appointed Andrew Matthews as operations director to maintain high performance standards and develop the business.
Matthews has more than 12 years’ experience in the pharmaceutical and healthcare industries. He has specialist knowledge in product areas for sterile and non-sterile medicines.
Matthews’ experience in quality driven operations management for unlicensed and licensed medicines will assist Quantum Pharmaceutical in its aim of strengthening links with hospitals, care home and home care pharmaceutical providers, as the company broadens its core customer base.
‘Andrew had an excellent CV and great track record as head of manufacturing ‘Specials’ with his former employer, domiciliary care organisation Healthcare At Home,’ said Andy Scaife, md of Quantum Pharmaceutical.
‘With knowledge of this niche sector of the pharmaceutical industry, Andrew is an excellent fit for Quantum but, most importantly, he brings a new skills set which will be of great benefit as we look to exploit new market opportunities.
Quantum Pharmaceutical appoints operations director
Andrew Matthews brings a new set of skills to the company
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months